Le remdésivir chez les patients atteints de la COVID-19

CMAJ. 2021 Apr 6;193(14):E495-E496. doi: 10.1503/cmaj.202505-f.
[Article in French]
No abstract available

MeSH terms

  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / therapeutic use
  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • COVID-19 / mortality
  • COVID-19 Drug Treatment*
  • Chemical and Drug Induced Liver Injury / etiology
  • Critical Care
  • Drug Hypersensitivity / etiology
  • Humans
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine